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Abnormal matrix metalloproteinase (MMP)-9 levels may have a role in
hypertensive disorders of pregnancy. We examined whether MMP-9 genetic
polymorphisms (g.1562C4T and g.90(CA)1325) modify plasma MMP-9
and tissue inhibitor of metalloproteinase (TIMP)-1 levels and the responses
to antihypertensive therapy in 214 patients with preeclampsia (PE), 185
patients with gestational hypertension (GH) and a control group of 214
healthy pregnant (HP). Alleles for the g.90(CA)1325 polymorphism were
grouped L (low) (o21 CA repeats) or H (high) (X21 CA repeats). Plasma
MMP-9 and TIMP-1 concentrations were measured by enzyme-linked
immunosorbent assay. Plasma MMP-9 concentrations were not affected
by genotypes or haplotypes in HP and PE groups, except for the
g.90(CA)1325 polymorphism: GH patients with the LH genotype for this
polymorphism have higher MMP-9 levels than those with other genotypes.
The T allele for the g.1562C4T polymorphism and the H4 haplotype
(combining T and H alleles) are associated with GH and lack of responsive-
ness to antihypertensive therapy in GH. The H2 haplotype (combining C and
H alleles) was associated with lack of responsiveness to antihypertensive
therapy in PE, but not in GH. In conclusion, our results show that MMP-9
genetic variants are associated with GH and suggest that MMP-9 haplotypes
affect the responsiveness to antihypertensive therapy in hypertensive
disorders of pregnancy.
The Pharmacogenomics Journal (2012) 12, 489–498; doi:10.1038/tpj.2011.31;
published online 19 July 2011
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Introduction
Preeclampsia (PE) and gestational hypertension (GH) are relatively common
hypertensive disorders of pregnancy associated with high maternal and fetal
mortality and morbidity. PE is a syndrome that only develops during pregnancy
and remits after delivery of the placenta, thus suggesting that its origin lies in
the placenta.1 Reduced placental perfusion leads to widespread maternal
vascular endothelial dysfunction by mechanisms involving the placental release
of vasopressors2 and other factors associated with oxidative stress and
inflammation into the maternal circulation.3,4
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Matrix metalloproteinases (MMPs) are a family of structu-
rally related enzymes that break down several extracellular
matrix components.5 Imbalanced MMP activities have been
reported in many clinical conditions affecting the cardio-
vascular system, including hypertensive disorders of preg-
nancy.6–10 Specifically, MMP-9 may be involved in placental
and uterine arterial remodeling11,12 and in the control of the
vascular tone.13,14 In addition, there is evidence that MMPs
interact with oxidative stress and inflammatory mediators
contributing to the endothelial dysfunction of PE patients.15
Therefore, the involvement of MMPs in the vascular
alterations of hypertensive disorders of pregnancy may
aggravate the lack of responses to antihypertensive therapy
in some patients.
While MMP-9 activity is regulated at different levels
including activation of latent forms, by interaction with
endogenous inhibitors, especially the tissue inhibitor
of metalloproteinase (TIMP)-1,16 it is also regulated at
the transcriptional level. In this respect, some genetic
polymorphisms in the MMP-9 gene clearly affect MMP-9
transcription.17 Two functional MMP-9 polymorphisms
include the single-nucleotide polymorphism g.1562C4T
and the microsatellite g.90(CA)1325. In vitro studies
showed that the ‘C’ to ‘T’ substitution at 1562 position
increases MMP-9 expression.17 However, the (CA)14 allele
causes a 50% reduction in MMP-9 promoter activity as
compared with the (CA)21.
18,19 Interestingly, these poly-
morphisms may affect drug responses20 and both poly-
morphisms have been associated with PE or GH,21,22 thus
suggesting that MMP-9 genetic variations may predispose to
hypertensive disorders of pregnancy. However, no previous
study has examined whether MMP-9 polymorphisms
affect MMP-9 levels in hypertensive disorders of pregnancy
and whether MMP-9 polymorphisms modify the antihyper-
tensive responses in these conditions.
In this study, we aimed at comparing the circulating
MMP-9 and TIMP-1 levels (and MMP-9/TIMP-1 ratio; an
index of net MMP-9 activity) in patients with hypertensive
disorders of pregnancy carrying different genotypes for the
two MMP-9 polymorphisms described above. Moreover, we
compared the distributions of MMP-9 genetic variants in GH
and PE patients who respond to antihypertensive therapy
with those found in GH and PE patients who do not respond
to antihypertensive therapy. We have also examined
whether MMP-9 haplotypes could have any effect on
MMP-9 levels and on the responses to antihypertensive
therapy.
Materials and methods
Subjects
Approval for use of human subjects was obtained from the
Institutional Review Board at the Faculty of Medicine of
Ribeirao Preto (University of Sao Paulo, Sao Paulo, Brazil).
All volunteers were consecutively enrolled in the Depart-
ment of Obstetrics and Gynecology, University Hospital
of the Faculty of Medicine of Ribeirao Preto. We studied 613
pregnants (214 healthy women with uncomplicated
pregnancies, 185 women with GH and 214 women with
PE). Hypertensive disorders were defined in accordance with
the NHBPEP (National High Blood Pressure Education
Program Working Group on High Blood Pressure in
Pregnancy).23 GH was defined as pregnancy-induced hyper-
tension (X140 mm Hg systolic or X90 mm Hg diastolic on
2 or more measurements at least 6 h apart) in a woman after
20 weeks of gestation, and returning to normal by 12 weeks
post-partum. PE was defined as GH plus significant protei-
nuria (X0.3 g/24 h). No women with pre-existing hyperten-
sion, with or without superimposed PE, were included
in this study.
At the time of clinic attendance, written informed consent
was provided and maternal venous blood samples were
collected. Genomic DNA was extracted from the cellular
component of 1 ml of whole blood by a salting-out method
and stored at 20 1C until analyzed. Plasma was obtained
from centrifugation of whole blood in ethylenediaminete-
traacetic acid at 2000 g for 10 min and stored at 70 1C until
assayed.
Genotyping
Genotypes for the g.1562C4T. polymorphism (rs3918242)
were determined by polymerase chain reaction as described
previously,24 using the primers 50-GCCTGGCACATAGTAGG
CCC-30 (sense) and 50-CTTCCTAGCCAGCCGGCATC-30
(antisense). The amplified products were digested with SphI
restriction enzyme (New England Biolabs, Ipswich, MA,
USA) overnight at 37 1C, producing fragments of 247 and
188 bp in the case of a polymorphic variant (allele T), or an
undigested 435 bp band in the case of a wild-type allele
(allele C). Fragments were separated by electrophoresis in
12% polyacrylamide gels and visualized by silver staining.
To determine the genotypes for the g.90(CA)1325
polymorphism (rs3222264), a polymerase chain reaction
was carried out as described previously,25 using the primers
50-GACTTGGCAGTGGAGACTGCGGGCA-30 (sense) and 50-GA
CCCCACCCCTCCTTGACAGGCAA-30 (antisense). The am-
plified products were separated in 7% polyacrylamide8 M
urea gel and visualized by silver staining. Differences
in number of bases, from 144 bp (CA 13 repeats) to 168 bp
(CA 25 repeats), were determined by comparison with
migration of a 10 bp DNA ladder (Invitrogen, Carlsbad,
CA, USA) and with some samples from homozygotes that
were sequenced. To make easier the interpretation of the
bands in the gel, the alleles were classified in accordance
with the biallelic distribution of this polymorphism:26,27
‘low’ (L) when the number of CA repeats was less than
21, and ‘high’ (H) when the number of CA repeats was
21 or more.
Antihypertensive treatment and drug response evaluation
The GH and PE patients in this study were carefully
monitored for signs and symptoms of PE, with fetal
surveillance and laboratory tests at least once weekly.
Responsiveness to therapy was based on the evaluation of
clinical and laboratory parameters (see below) in response to
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the administration of antihypertensive drugs. The initial
antihypertensive drug of choice was methyldopa (1000–
1500 mg per day), followed by nifedipine (40–60 mg per day)
and/or hydralazine (5–30 mg per day), which were added in
case of lack of significant responses to methyldopa. The
following clinical laboratory outcomes were considered as
reflecting a lack of response to therapy:23,28
(1) clinical symptoms including blurred vision, persistent
headache or scotomata, persistent right upper quadrant
or epigastric pain;
(2) systolic blood pressure above 140 mm Hg and diastolic
blood pressure above 90 mm Hg, as assessed by the blood
pressure curve;
(3) HELLP (hemolysis, elevated liver enzymes and a
low platelet count) syndrome; proteinuria 42.0 g/24 h;
creatinine 41.2 mg/100 ml or blood urea nitrogen
430 mg/100 ml; aspartate aminotransferase 440 U l1
and alanine aminotransferase 460 U l1; and
(4) fetal hypoactivity or non-reactive fetus, as revealed by
cardiotocography; intrauterine growth restriction, oli-
goamnio, abnormal biophysical profile score, Doppler
velocimetry abnormalities, as evaluated by ultrasound.
We excluded four GH patients and one PE patient from
analysis because some laboratory tests were missing, making
it impossible to classify them with certainty.
Enzyme immunoassays of plasma MMP-9 and TIMP-1
Plasma MMP-9 and TIMP-1 concentrations were measured
by a commercially available sandwich enzyme-linked im-
munosorbent assay kit (DY911 and DY970, respectively;
R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions.
Statistical analysis
Statistical analysis was carried out using the Stat-View (SAS
Institute, Cary, NC, USA). The clinical characteristics,
plasma MMP-9 and TIMP-1 concentrations and MMP-9/
TIMP-1 ratio of women with GH or PE were compared with
those found in healthy pregnant (HP) women by Student’s
unpaired t-test, Mann–Whitney U-test or w2 as appropriate.
The distribution of genotypes for each polymorphism was
assessed for deviation from the Hardy–Weinberg equili-
brium, and differences in genotype and allele frequencies
among groups were assessed using w2 test or Fisher’s
exact test. A value of Po0.05 was considered statistically
significant.
The Bayesian statistical-based program Phase 2.1 was used
to estimate the haplotype frequencies in each group. The
possible haplotypes including genetic variants for two
MMP-9 polymorphisms studied (C or T variants for the
g.1562C4T and L or H variants for g.90(CA)1325) were:
H1 (CL), H2 (CH), H3 (TL) and H4 (TH). Differences in
haplotype frequency were further tested using contingency
tables. The minimum level of statistical significance was
corrected for the number of comparisons made. Therefore,
we considered significant Po0.05/number of haplotypes
(Po0.05/3¼0.0167). We excluded the rare haplotype
(H3 frequency o0.1%) from the analysis.
Linear regression analysis and nonlinear fitting routines
were performed using the software JMP 5.0.1a (SAS Institute)
to assess univariate relations between variables. In addition,
a bivariate analysis was also performed to assess the
potential confounding influence of each covariate on the
relation between MMP-9/TIMP-1 levels and MMP-9 geno-
types/haplotypes in HP, GH and PE groups. The variables of
clinical importance were then included in multiple linear or
logistic regression models. Plasma MMP-9 concentration,
plasma TIMP-1 concentration, MMP-9/TIMP-1 ratio, respon-
siveness to methyldopa and responsiveness to therapy were
considered as dependent variables. MMP-9 genotypes/
haplotypes, age, ethnicity, smoking, body mass index,
primiparity and gestational age at sampling were considered
as independent variables.
Results
Table 1 summarizes the characteristics of pregnant enrolled
in this study. HP, GH and PE women showed similar
ethnicity (% white), % current smoking, hemoglobin,
hematocrit and creatinine (all P40.05). As expected, PE
and GH presented higher systolic and diastolic blood
pressure compared with HP (both Po0.05). It should be
noted, however, that most patients were receiving anti-
hypertensive therapy. GH and PE were slightly older than
HP (Po0.05). Increased body mass index and fasting glucose
was found in GH and PE patients compared with HP group
(all Po0.05). We found lower gestational age at delivery in
GH and PE, lower newborn weights in PE and lower %
primiparity in GH (all Po0.05) compared with HP.
Significant proteinuria was found in PE. Supplementary
Tables S1 and S2 show the characteristics of pregnants in the
GH and PE groups classified according to responsiveness
to methyldopa and to the total therapy (Supplementary
Tables S1 and S2).
Although we found higher plasma MMP-9 and TIMP-1
concentrations in GH patients compared with HP patients
(Figure 1; both Po0.05), the MMP-9/TIMP-1 ratios were not
different (Figure 1; P40.05). TIMP-1 levels were higher in PE
women compared with HP (Figure 1; Po0.05). However,
MMP-9 and MMP-9/TIMP-1 ratios were similar in PE and HP
(Figure 1; P40.05).
The results for MMP-9 single-locus analyses are shown in
Supplementary Table S3. The distribution of genotypes for
the two polymorphisms studied showed no deviation from
HardyWeinberg equilibrium (all P40.05). With respect to
the g.90(CA)1325 polymorphism, we found no significant
differences in genotype and allele frequencies when PE or
GH group were compared with HP group (all P40.05;
Supplementary Table S3). However, the genotype and
allele frequencies for g.1562C4T polymorphism were
different in the GH group compared with HP (Po0.05).
The CT genotype and T allele were more commonly found
in the GH group than in the HP group (both Po0.05;
MMP-9 polymorphisms and antihypertensive therapy
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Supplementary Table S3). Conversely, we found no differ-
ences in genotype or allele frequencies for the g.1562C4T
polymorphism when the PE and the HP groups were
compared (all P40.05; Supplementary Table S3).
The results for MMP-9 haplotype analyses are shown in
Supplementary Table S4. Although we found no differences
when the PE group was compared with HP (P40.05;
Supplementary Table S4), the distribution of MMP-9 haplo-
types in the GH group was different than that found in the
HP group. We found that the H4 haplotype (T H) was more
commonly found in the GH group than in the HP
(Po0.0167; Supplementary Table S4).
To determine the influence of MMP-9 genotypes on
plasma MMP-9 and TIMP-1 levels, we performed a multiple
linear regression analysis adjusting for age, ethnicity,
current smoking, body mass index, primiparity and gesta-
tional age at sampling (Table 2). We found that the LH
genotype for the g.90(CA)1325 polymorphism was sig-
nificantly and positively associated with plasma MMP-9
concentration and MMP-9/TIMP-1 ratio in GH group
(Table 4; both Po0.05). Moreover, ethnicity was associated
with TIMP-1 levels in the GH group, and age and primiparity
were positively associated with TIMP-1 in PE group
(Table 2; all Po0.05).
We determined the influence of MMP-9 haplotypes on
plasma MMP-9 and TIMP-1 levels. We performed another
multiple linear regression analysis adjusting for the same
factors cited above and we found no significant effects of
MMP-9 haplotypes on plasma MMP-9 and TIMP-1 concen-
trations in the HP, GH and PE groups (Table 3; all P40.05).
Gestational age at sampling was negatively associated with
MMP-9 levels in the HP group (Table 3; Po0.05). Ethnicity,
smoking status and primiparity were positively associated
with TIMP-1 in GH group (Table 3, all Po0.05). Ethnicity
affected MMP-9 levels and MMP-9/TIMP-1 ratio in the PE
group, whereas age and primiparity affected TIMP-1 levels in
this group (Table 3; all Po0.05).
The results for MMP-9 single-locus analyses with respect
to the responses to methyldopa and to the total antihyper-
tensive therapy are shown in the Tables 4 and 5, respectively.
These results were adjusted for age, ethnicity, current
smoking, body mass index, and primiparity in a multiple
logistic regression. Interestingly, the CT or the TT genotypes
for the g.1562C4T polymorphism were more common in
GH patients non-responsive to methyldopa or to the total
therapy (Tables 4 and 5, respectively; both Po0.05).
Conversely, this polymorphism apparently has no effects
on the responsiveness to therapy in the PE group (Tables 4
and 5; P40.05). The g.90(CA)1325 polymorphism, how-
ever, has no effects on antihypertensive therapy in both GH
and PE groups (Tables 4 and 5; all P40.05). It should be
noted that this polymorphism tended to have some effects
in the PE group (P¼0.054 and 0.058 for the responses to
methyldopa and to the total antihypertensive therapy,
respectively; Tables 4 and 5, respectively).
The results for MMP-9 haplotypes analyses with respect to
the responses to methyldopa and to the total antihyperten-
sive therapy are shown in the Tables 6 and 7, respectively.
These results were adjusted for the same variables cited
above in a multiple logistic regression. Interestingly, the
haplotype H4 (T H) was more frequent in GH patients non-
responsive to methyldopa or to the total antihypertensive
Table 1 Demographic characteristics of study subjects
Parameters Healthy pregnant
(n¼ 214)
Gestational hypertension
(n¼185)
P-value Preeclampsia
(n¼214)
P-value
Age (years) 24.5±0.4 27.0±0.5* 0.000 26.0±0.5* 0.003
Ethnicity (% White) 71.5 73.3 0.704 69.9 0.718
Current Smoking (%) 12.6 11.2 0.689 8.7 0.205
BMI (kgm2) 23.3±0.3 29.5±0.5* 0.000 27.2±0.4* 0.000
SBP (mmHg) 112.1±0.7 133.4±1.1* 0.000 142.3±1.1* 0.000
DPB (mmHg) 72.2±0.5 84.2±0.8* 0.000 88.9±0.7* 0.000
HR (beatsmin1) 82.3±0.6 82.0±0.5 0.749 82.7±0.5 0.680
Fasting glucose (mgdl1) 75.1±1.0 79.2±1.1* 0.005 79.2±1.8* 0.047
Hb (gdl1) 11.9±0.1 11.9±0.1 0.885 12.0±0.1 0.718
Hct (%) 35.7±0.4 35.8±0.3 0.808 36.1±0.3 0.400
Creatinine (mmol l1) 58.9±2.6 55.1±0.8 0.190 62.6±1.4 0.746
24-h Pr (mg/24h) ND 134.5±9.3 1333.0±151.0** 0.000
Primiparity (%) 50.3 39.9* 0.042 44.5 0.243
GAD (weeks) 39.8±0.1 38.8±0.1* 0.000 36.0±0.3* 0.000
Newborn weight (g) 3316.0±34.6 3202.0±41.7 0.095 2546.0±64.7* 0.000
GAS (weeks) 36.8±0.2 36.0±0.4 0.330 34.2±0.4* 0.000
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; GAD, gestational age at delivery; GAS, gestational age at sampling; 24-h Pr, 24-h proteinuria;
Hb, hemoglobin concentration; Hct, hematocrit; HR, heart rate; ND, not determined (however, negative dipstick test); SBP, systolic blood pressure.
Values are the mean±s.e.m.
*Po0.05 vs healthy pregnant group.
**Po0.05 vs gestational hypertension group.
MMP-9 polymorphisms and antihypertensive therapy
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therapy (Tables 6 and 7; both Po0.05). Moreover, the H2
(C H) haplotype was more frequent in PE patients non-
responsive to methyldopa or to the total antihypertensive
therapy (Tables 6 and 7; both Po0.05). Conversely, the H2
haplotype was more common in GH patients responsive to
the total antihypertensive therapy (Table 7; Po0.05).
Discussion
Despite the fact that hypertensive disorders of pregnancy are
leading causes of maternalfetal mortality and morbidity,
there is no effective drug treatment for these conditions, and
current management options have limitations. In this study,
we analyzed the influence of two MMP-9 polymorphisms on
plasma MMP-9 and TIMP-1 levels and on the responsiveness
to antihypertensive therapy. Our findings may help to
understand the relevance of MMP-9 and its genetic poly-
morphisms to the pathophysiology and therapeutic re-
sponses of hypertensive disorders of pregnancy.
The circulating MMP-9 and TIMP-1 levels reported in this
study are consistent with previous results, which indicate
higher MMP-97 and TIMP-17,9,10 levels in hypertensive
disorders of pregnancy compared with those found in HP.
Table 4 Genotype frequencies of MMP-9 polymorphisms according to responsiveness to methyldopa
Genotype GH—Methyldopa responsiveness PE—Methyldopa responsiveness
R (n¼125) NR (n¼56) OR (95% CI) P-value R (n¼61) NR (n¼152) OR (95% CI) P-value
MMP-9 CC 93 (74%) 33 (59%) 1.00 (reference) 46 (75%) 120 (79%) 1.00 (reference)
C1562T CT+TT 32 (26%) 23 (41%) 2.23 (1.06–4.73)* 0.036 15 (25%) 32 (21%) 0.62 (0.28–1.39) 0.240
MMP-9 LL 21 (17%) 8 (14%) 1.00 (reference) 18 (29%) 26 (17%) 1.00 (reference)
g.90(CA)1325 LH 65 (52%) 31 (56%) 1.27 (0.49–3.33) 0.629 26 (43%) 65 (43%) 1.23 (0.53–2.92) 0.637
HH 39 (31%) 17 (30%) 0.79 (0.25–2.40) 0.677 17 (28%) 61 (40%) 2.61 (1.00–7.16) 0.054
Abbreviations: BMI, body mass index; CI, confidence interval; GH, gestational hypertension; MMP-9, matrix metalloproteinase-9; NR, non-responsive; OR, odds ratio;
PE, preeclampsia; R, responsive.
The genotype distribution was adjusted for age, ethnicity, current smoking, BMI and primiparity.
*Po0.05 vs responsive GH.
Table 5 Genotype frequencies of MMP-9 polymorphisms according to responsiveness to total antihypertensive therapy
Genotype GH—Therapy responsiveness PE—Therapy responsiveness
R (n¼159) NR (n¼22) OR (95% CI) P-value R (n¼114) NR (n¼99) OR (95% CI) P-value
MMP-9 CC 114 (72%) 12 (55%) 1.00 (reference) 88 (77%) 78 (79%) 1.00 (reference)
C1562T CT 45 (28%) 10 (45%) 2.81 (1.00–8.10)* 0.049 26 (23%) 21 (21%) 0.66 (0.32–1.35) 0.259
MMP-9 LL 25 (16%) 4 (18%) 1.00 (reference) 27 (24%) 17 (17%) 1.00 (reference)
g.90(CA)1325 LH 85 (53%) 11 (50%) 0.85 (0.21–3.52) 0.817 50 (44%) 41 (42%) 1.02 (0.47–2.24) 0.963
HH 49 (31%) 7 (32%) 0.76 (0.15–3.59) 0.725 37 (32%) 41 (41%) 2.31 (0.98–5.55) 0.058
Abbreviations: BMI, body mass index; CI, confidence interval; GH, gestational hypertension; MMP-9, matrix metalloproteinase-9; NR, non-responsive; OR, odds ratio;
PE, preeclampsia; R, responsive.
The genotype distribution was adjusted for age, ethnicity, current smoking, BMI and primiparity.
*Po0.05 vs responsive GH.
Table 6 Haplotype frequencies of MMP-9 polymorphisms according to responsiveness to methyldopa
Haplotype GH—Methyldopa responsiveness PE—Methyldopa responsiveness
R (n¼1252) NR (n¼562) OR (95% CI) P-value R (n¼612) NR (n¼1522) OR (95% CI) P-value
H1 (C L) 107 (43%) 46 (41%) 1.00 (reference) 62 (51%) 116 (38%) 1.00 (reference)
H2 (C H) 110 (44%) 41 (37%) 0.58 (0.29–1.14) 0.115 44 (36%) 154 (51%) 2.04 (1.05–3.96)** 0.034
H4 (T H) 33 (13%) 24 (21%) 2.32 (1.00–5.30)* 0.047 16 (13%) 33 (11%) 0.76 (0.32–1.92) 0.547
Abbreviations: BMI, body mass index; CI, confidence interval; GH, gestational hypertension; MMP-9, matrix metalloproteinase-9; NR, non-responsive; OR, odds ratio;
PE, preeclampsia; R, responsive.
The haplotype distribution was adjusted for age, ethnicity, current smoking, BMI and primiparity.
*Po0.05 vs responsive GH.
**Po0.05 vs responsive PE.
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It is possible that MMP-9 released by endothelial and
smooth muscle cells during hypertensive disorders leads to
cardiovascular alterations associated with hypertension.29
However, because TIMP-1 is an important endogenous
MMP-9 inhibitor, the increased TIMP-1 levels found in both
PE and GH has led to similar MMP-9/TIMP-1 ratios in PE and
GH compared with HP, thus suggesting that similar net
MMP-9 activity exist in patients with hypertensive disorders
of pregnancy as compared with HP.
Although our results confirm previous findings showing
that the g.1562C4T polymorphism is associated with GH
and not with PE,22 the g.1562C4T polymorphism had no
significant effects on MMP-9 levels and MMP-9/TIMP-1
ratios in the three study groups, although an in vitro study
showed that the T allele is associated with increased MMP-9
expression.17 Conversely, the g.90(CA)1325 polymor-
phism affected the circulating MMP-9 levels and MMP-9/
TIMP-1 ratios in the GH group, and this finding is consistent
with in vitro studies suggesting functional implications for
this polymorphism.18,19 Taken together, these findings may
be of limited utility to understand how MMP-9 gene
variations affect MMP-9 levels or MMP-9/TIMP-1 ratios.
Therefore, we carried out haplotype analysis, which could be
more effective in providing relevant information.
The haplotype analyses showed that H4 haplotype
(combining the T allele for the g.1562C4T and H allele
for the g.90(CA)1325 polymorphism) increases the sus-
ceptibility to GH, and no significant association was found
with respect to PE. Moreover, MMP-9 haplotypes apparently
had no effects on plasma MMP-9 levels of MMP-9/TIMP-1
ratios. These findings suggest that the possible contribution
of MMP-9 to hypertensive disorders of pregnancy are
not clearly reflected by the circulating levels of this MMP.
Indeed, the origin of circulating MMP-9 measured in
the blood is unknown, even though placental tissue may
contribute to it.11,12 There is evidence, however, that
circulating activated neutrophils and monocytes may
release MMP-9 as a consequence of a general inflammatory
state in hypertensive disorders of pregnancy.15 However, the
placenta is mostly a fetal tissue and therefore it is possible
that fetal MMP-9 genotypes contributes to MMP-9 levels and
to the development of hypertensive disorders of pregnancy,
although this remains to be defined.30 Examining how the
maternal MMP-9 haplotypes interact with fetal MMP-9
haplotypes is beyond the scope of this study.
Antihypertensive drugs do not prevent the pathophysio-
logical alterations of PE. However, they allow maintenance
of pregnancy and promote an increased gestational age
of delivery, thus decreasing adverse maternal and fetal
outcomes.31 In this respect, while some antihypertensive
drugs can downregulate MMPs’ activities32–35 and as this
effect may contribute to the reduction of blood pressure, no
previous study had examined whether MMP-9 polymor-
phisms affect the antihypertensive effects of drugs used to
treat hypertensive disorders of pregnancy. In this study, we
investigated for the first time the effects of MMP-9
polymorphisms in responsiveness to methyldopa or to total
antihypertensive therapy in hypertensive disorders of
pregnancy. Although the g.90(CA)1325 polymorphism
apparently had now major effects, the g.1562C4T poly-
morphism was significantly associated with the antihyper-
tensive responses. The CT/TT genotypes were associated
with lack of responses to methyldopa and to the total
therapy used in this study in GH, but not in PE. Interest-
ingly, the T allele was associated with increased suscep-
tibility to GH, and not to PE. These findings suggest that the
g.1562C4T polymorphism not only promotes GH, but
also decreases the responses to antihypertensive therapy.
We have also examined whether MMP-9 haplotypes affect
the responsiveness to methyldopa or to total antihyperten-
sive therapy. Our results showed that the H4 haplotype was
associated with lack of response to methyldopa and to the
total therapy in the GH group, whereas the H2 haplotype
decreases the responsiveness to antihypertensive therapy in
the PE group. However, the H2 haplotype was more frequent
in responsive than in non-responsive GH patients. Interest-
ingly, the H4 haplotype combines the two MMP-9 variants
associated with increased in vitro MMP-9 levels expres-
sion.17–19 Although we have not found increased MMP-9
levels in subjects carrying the H4 haplotype, it is possible
that the circulating MMP-9 levels do not reflect tissue MMP-
9 levels, as discussed above. Supporting this suggestion,
we found that the H4 haplotype was associated with GH.
Interestingly, we found that only the g.90(CA)1325
polymorphism was associated with MMP-9 plasma levels
in GH, and this polymorphism apparently does not affect
Table 7 Haplotype frequencies of MMP-9 polymorphisms according to responsiveness to total antihypertensive therapy
Haplotype GH—Therapy responsiveness PE—Therapy responsiveness
R (n¼1592) NR (n¼222) OR (95% CI) P-value R (n¼1142) NR (n¼992) OR (95% CI) P-value
H1 (C L) 134 (42%) 19 (43%) 1.00 (reference) 104 (46%) 74 (37%) 1.00 (reference)
H2 (C H) 138 (43%) 13 (30%) 0.37 (0.14–0.96)* 0.045 96 (42%) 102 (52%) 1.90 (1.06–3.45)** 0.033
H4 (T H) 45 (14%) 12 (27%) 3.51 (1.19–9.75)* 0.018 28 (12%) 21 (11%) 0.73 (0.31–1.66) 0.454
Abbreviations: BMI, body mass index; CI, confidence interval; GH, gestational hypertension; MMP-9, matrix metalloproteinase-9; NR, non-responsive; OR, odds ratio;
PE, preeclampsia; R, responsive.
The haplotype distribution was adjusted for age, ethnicity, current smoking, BMI and primiparity.
*Po0.05 vs responsive GH.
**Po0.05 vs responsive PE.
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the responsiveness to antihypertensive therapy. Conversely,
the g.1562 C4T polymorphism and the H4 haplotype,
which were associated with GH and impaired the respon-
siveness to antihypertensive therapy, had no significant
effects on plasma MMP-9 levels. These findings suggest that
the circulating MMP-9 levels may have little predictive value
for antihypertensive therapy. Moreover, MMP-9 levels may
not reflect the possible contribution of MMP-9 genotypes
or haplotypes to hypertensive disorders of pregnancy or to
antihypertensive therapy. Indeed, our results do not rule out
a possible contribution of MMP-9 genotypes or haplotypes
to variations in MMP-9 levels in placental and uterine
arterial tissues, which may be very relevant to hypertensive
disorders of pregnancy.11,12
We found significant differences between GH and PE with
respect to their possible associations with MMP-9 poly-
morphisms. Importantly, while the H2 haplotype was more
frequent in patients with PE that do not respond to the
antihypertensive therapy, the same H2 haplotype was more
prevalent in GH patients who respond to the therapy. Our
findings do not provide a reliable basis to explain such a
difference between these hypertensive disorders of preg-
nancy. However, this finding is consistent with the sugges-
tion that different mechanisms may have a role in these
diseases. In addition, although we have studied a significant
number of patients, it is possible that studying a greater
number of subjects would allow us to detect other
significant associations.
The criteria used in this study to assess the responses to
antihypertensive therapy may have affected our results and
conclusions. Although there is no clear definition of how to
precisely assess the severity of hypertensive disorders of
pregnancy, it is possible that responsiveness to therapy
reflects disease severity, and additional studies are needed to
improve our understanding of these syndromes. However,
we could speculate that GH patients carrying the C allele for
the 1562 C4T polymorphism, or with the H4 haplotype,
which were associated with GH and impaired the respon-
siveness to antihypertensive therapy, could benefit from the
use of MMPs inhibitors, such as doxycycline. It is possible
that patients with these genetic markers have increased
tissue levels of MMP-9, as previous studies suggest,17–19 even
though we have not found increased plasma MMP-9 level
patients carrying these markers. Whether these patients
would have improved outcomes after the use of MMPs
inhibitors remains to be determined.
In conclusion, we found evidence indicating that the T
allele for the g.1562C4T polymorphism and the H4
haplotype are associated with GH and with lack of respon-
siveness to antihypertensive therapy in GH, although they do
not affect MMP-9 levels. In addition, while we found
increased MMP-9 levels in GH patients with the LH genotype
for the g.90(CA)1325 polymorphism, we found no effects of
MMP-9 haplotypes on MMP-9 levels. Finally, the H2 haplo-
type was associated with lack of responsiveness to antihyper-
tensive therapy in PE, but not in GH. Overall, our findings
indicate that MMP-9 haplotypes affect the susceptibility to
hypertensive disorders of pregnancy and the antihypertensive
responses to drugs used in these conditions.
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Figure 1 Plasma matrix metalloproteinase-9 (MMP-9) (a) and tissue
inhibitor of metalloproteinase-1 (TIMP-1) (b) concentrations, and
MMP-9/TIMP-1 ratios (c) in health pregnant (HP), gestational hyperten-
sion (GH) and preeclampsia (PE). The bars show the means±s.e.m.
*Po0.05 vs HP.
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